|Bid||84.11 x 200|
|Ask||84.12 x 2500|
|Day's Range||84.02 - 84.34|
|52 Week Range||66.93 - 86.90|
|PE Ratio (TTM)||31.70|
|Dividend & Yield||2.72 (3.27%)|
|1y Target Est||N/A|
Novartis (NVS) released its 2Q17 earnings on July 18, 2017. It reported flat revenues at constant exchange rates compared to 2Q16.
Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen.
Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.